BCL2 and lymphoid neoplasm: Co-expression of MYC with BCL-XL or BCL-2 also influenced the tumor phenotype; Rather than a mixed phenotype of myeloid and T lymphoid tumors, development of an aggressive AML-like disease was favored (Figure 6).